← Compound index
COMPOUND RECORD / ADK-918

ADK-918АДК-918

The para-bromobenzamide counterpart of Chlodantane, N-(adamantan-2-yl)-4-bromobenzamide. It is chemically distinct from Bromantane.

Performance
Source linked

What the studies found

Animal research · 2023

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

Findings for this preparation

Complexation of ADK-918 neutralized its actoprotective effect in the tested animal preparation. The treadmill improvement reported for a separate camphane candidate is not an ADK-918 benefit.

Study notes · methods, sources and limitations

Participants or model Mouse pharmacology experiments

Important limitations

  • Abstract-level animal findings do not establish human performance benefits or improved clinical safety. An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose. The Russian and English versions are one publication, not independent replication.

Pharmaceutical Chemistry Journal. 57(4):523–534 · Publication record

Original source or citation ↗

Study results and tables ↗

Laboratory analysis · 2019

Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes

Study of multiple preparations

The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.

Study notes · methods, sources and limitations

Participants or model Chemical synthesis and characterization; background pharmacology citations

Important limitations

  • Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy. ADK-957’s original cold-exposure experiment and detailed safety data remain acquisition targets.

Russian Journal of General Chemistry. 89(3):399–404 · Publication record

Original source or citation ↗

Study results and tables ↗

Animal research

Role of neurotropic adamantane-containing compounds in the regulation of immunity

Study of multiple preparations

The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.

Study notes · methods, sources and limitations

Participants or model Multiple mouse strains and laboratory immune assays

Important limitations

  • OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata. Immune and colony assays do not demonstrate better health, infection prevention or long-term stem-cell expansion in people.

Dissertation author’s abstract; third-party Russian transcription · Dissertation; OCR reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About ADK-918

Names in this research collection

ADC-918

Compound class
Experimental adamantane / analogue
Research collection
Actoprotection & occupational pharmacology · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Human efficacy results unavailable

Study methods

Source-specific animal, chemistry, patent or dissertation evidence

Independent replication

Independent replication not established; translations are not separate experiments

Source access

Access and review depth appear with each linked record

Safety evidence

Human safety and interactions not established; animal activity is not a safe-use recommendation

Open a topic for the evidence assessment.

More findings, background and history

Chlodantane, Cyclontane and the ADK research program ↗

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2018 · RU2660654C1 · Phenoxyacetamide structural analogues of Chlodantane and ADK-918Platform context · 15.1 g, 85% yield

Reported findings

The disclosure reports synthesis yields; it does not supply a verified clinical adaptogenic result.

Analogue 1 recovery
15.1 g, 85% yieldManufacturing result for the newly claimed analogue, not Chlodantane or ADK-918
Analogue 2 recovery
80% yield; melting interval 94.5–95.0°CA different new analogue; analytical characterization
All reported results, comparisons and limitations →

Platform context. The claimed phenoxyacetamides are described as structural analogues of ADK-910 and ADK-918, rather than claims to those reference compounds themselves.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2660654C1 ↗ · 2018-07-09
Earliest priority / filing
2017-06-09 / 2017-06-09
Original applicant / assignee
Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ)
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
62815866 · family publications are related filings, not independent studies.
Original title, inventors and related publications

N-(adamantan-2-yl)- and n-[(adamantan-1-yl)methyl]- derivatives of 2-(4-allyl-2-methoxyphenoxy)acetic acid amide, which are potential synthetic adaptogens of emergency action

Inventors: Иван Александрович Новаков; Лейла Липпаритовна Брунилина; Андрей Александрович Вернигора; Максим Борисович Навроцкий; Борис Семёнович Орлинсон; Александр Сергеевич Яблоков.

RU2660654C1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2023

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

Complexation of ADK-918 neutralized its actoprotective effect in the tested animal preparation. The treadmill improvement reported for a separate camphane candidate is not an ADK-918 benefit.

Study notes and original source
2023Animal / experimentalFull text available

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al. · Pharmaceutical Chemistry Journal. 57(4):523–534

The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.

Population / setting
Mouse pharmacology experiments
Source reviewed
Institute abstract and selected author-uploaded full-text passages checked, including the 7/14-day schedule and baseline-imbalance discussion; complete tables not independently appraised.
Study limitations
  • Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
  • An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose.
  • The Russian and English versions are one publication, not independent replication.

Reviewed 2026-10-03.

Read the source ↗

Laboratory analysis · 2019

Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes

The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.

Study notes and original source
2019Analytical / composition studyFull text available

Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes

I. A. Novakov, R. V. Brunilin, G. M. Butov, A. A. Vernigora, M. B. Navrotskii, A. S. Yablokov, S. N. Voloboev · Russian Journal of General Chemistry. 89(3):399–404

The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.

Population / setting
Chemical synthesis and characterization; background pharmacology citations
Source reviewed
Author-uploaded paper’s accessible chemistry/background passages checked; earlier pharmacology not independently recovered.
Study limitations
  • Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy.
  • ADK-957’s original cold-exposure experiment and detailed safety data remain acquisition targets.

Reviewed 2026-10-03.

Read the source ↗

Animal research · Year unconfirmed

Role of neurotropic adamantane-containing compounds in the regulation of immunity

The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.

Study notes and original source
Year unconfirmedAnimal / experimentalRussian-language source

Role of neurotropic adamantane-containing compounds in the regulation of immunity

· Dissertation; OCR reproduction

Format: Dissertation abstract transcription · Reviewed: See scope

· Dissertation author’s abstract; third-party Russian transcription

The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.

Population / setting
Multiple mouse strains and laboratory immune assays
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata.
  • Immune and colony assays do not demonstrate better health, infection prevention or long-term stem-cell expansion in people.

Reviewed 2026-10-03.

Read the source ↗

Animal research · 1996

Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects

ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.

Study notes and original source
1996Animal / experimentalRussian-language source

Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects

· Dissertation; OCR reproduction

Format: Dissertation abstract transcription · Reviewed: See scope

T. G. Khlopushina · Doctoral dissertation author’s abstract. Moscow, 1996

ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.

Population / setting
Mouse hepatic-enzyme screening and sensitized guinea-pig anaphylaxis experiments
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • Original structures and tables require checking against the scan; transcription errors are possible.
  • Enzyme induction does not establish detoxification benefits or predict safe human drug combinations.
  • Animal anaphylaxis results are not evidence for treating allergy in people; proposed adjunct uses were development suggestions.

Reviewed 2026-10-03.

Read the source ↗

Experiment described in a patent · 1996

Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation

The abstract claims protection during overheating, hypobaric hypoxia and water deprivation, and improved rat operant activity under fatigue. Filing dates to 13 July 1989; publication was 10 June 1996.

Study notes and original source
1996Patent / reported experimentsBibliographic record

Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation

· SU1646256A1

The abstract claims protection during overheating, hypobaric hypoxia and water deprivation, and improved rat operant activity under fatigue. Filing dates to 13 July 1989; publication was 10 June 1996.

Results and tables

Reported patent results

Experimental results unavailable in the source

Experimental results could not be extracted from the accessed source; the later Chlodantane formulation patent is a separate disclosure.

The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.

Population or model The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.

Results · Accessed original-publication index entry; description and result tables unavailable.
MeasureResultComparison, timing and statistics
Original experimental outcomesNot available in the accessed bibliographic entryNo animal survival percentage or human performance effect is invented

The original certificate is unavailable. Whether it contains experimental results remains unknown.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
Source reviewed
Bibliographic index entry accessed. No readable original experimental description or results tables were available; quantitative extraction requires the original publication.
Study limitations
  • Only the patent abstract and metadata were recovered; the two experimental tables remain unavailable.
  • Abstract toxicity figures lack adequate species/route context here and are not used to rank safety.

Reviewed 2026-11-06.

Read the source ↗

Experiment described in a patent · 2018

Phenoxyacetamide structural analogues of Chlodantane and ADK-918

The patent explicitly identifies its two adamantane-containing phenoxyacetamides as structural analogues of ADK-910 and ADK-918. This documents a later medicinal-chemistry branch, not demonstrated clinical superiority.

Study notes and original source
2018Patent / reported experimentsFull text available

Phenoxyacetamide structural analogues of Chlodantane and ADK-918

· RU2660654C1; Volgograd State Technical University

The patent explicitly identifies its two adamantane-containing phenoxyacetamides as structural analogues of ADK-910 and ADK-918. This documents a later medicinal-chemistry branch, not demonstrated clinical superiority.

Results and tables

Reported patent results

Reported findings

The disclosure reports synthesis yields; it does not supply a verified clinical adaptogenic result.

Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.

Population or model Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.

Results · Final two chemical examples and characterization results.
MeasureResultComparison, timing and statistics
Analogue 1 recovery15.1 g, 85% yieldManufacturing result for the newly claimed analogue, not Chlodantane or ADK-918
Analogue 2 recovery80% yield; melting interval 94.5–95.0°CA different new analogue; analytical characterization

Chemical yields do not establish biological adaptogenic activity. The claimed compounds are structural analogues of the reference candidates, not the candidates themselves.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Chemistry and preclinical observations do not establish human efficacy or safety.

Reviewed 2026-11-06.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗